Long non-coding RNA(lncRNA) is a kind of non-coding RNA with a length of more than 200 nucleotides mainly distributed in a variety of eukaryotic cells. It cannot encode proteins itself. With the development of gene sequencing technology, the molecular pathogenesis of venous malformation is getting deeper and deeper. Abnormal expression of lncRNA may be closely related to the occurrence and development of venous malformations. LncRNA can selectively regulate the proliferation, apoptosis and migration of endothelial cells and vascular smooth muscle cells, thus the occurrence and development of venous malformations is affected. Therefore, lncRNA is expected to be a novel diagnostic marker or a new therapeutic target for venous malformations.

Long non-coding RNA(lncRNA) is a kind of non-coding RNA with a length of more than 200 nucleotides mainly distributed in a variety of eukaryotic cells. It cannot encode proteins itself. With the development of gene sequencing technology, the molecular pathogenesis of venous malformation is getting deeper and deeper. Abnormal expression of lncRNA may be closely related to the occurrence and development of venous malformations. LncRNA can selectively regulate the proliferation, apoptosis and migration of endothelial cells and vascular smooth muscle cells, thus the occurrence and development of venous malformations is affected. Therefore, lncRNA is expected to be a novel diagnostic marker or a new therapeutic target for venous malformations.

Long non-coding RNA (lncRNA) is a kind of non-coding RNA with a length of more than 200 nucleotides mainly distributed in a variety of eukaryotic cells. It cannot encode proteins itself. With the development of gene sequencing technology, the clinical understanding of venous malformation, molecular pathogenesis of vascular malformation, is getting deeper and deeper. Abnormal expression of lncRNA may be closely related to the occurrence and development of venous malformations. LncRNA can selectively regulate the proliferation, apoptosis and migration of endothelial cells and vascular smooth muscle cells, thus affecting the occurrence and development of venous malformations. Therefore, lncRNA is expected to be a novel diagnostic marker or a new therapeutic target for venous malformations.

Long non-coding RNA (lncRNA) is a kind of non-coding RNA with a length of more than 200 nucleotides mainly distributed in a variety of eukaryotic cells. It cannot encode proteins itself. With the development of gene sequencing technology, the clinical understanding of venous malformation, molecular pathogenesis of vascular malformation, is getting deeper and deeper. Abnormal expression of lncRNA may be closely related to the occurrence and development of venous malformations. LncRNA can selectively regulate the proliferation, apoptosis and migration of endothelial cells and vascular smooth muscle cells, thus affecting the occurrence and development of venous malformations. Therefore, lncRNA is expected to be a novel diagnostic marker or a new therapeutic target for venous malformations.

Giant lymphatic vascular malformation with intracapsular hemorrhage is rare in neonates, and its incidence gradually increased in recent years. In consideration of physiological characteristics of neonates, the treatment is of great value. In January 2021, a 1-hour-old boy with facial and cervical giant lymphatic malformation and intracapsular hemorrhage was admitted to the Department of Hemangioma Surgery, the Third Affiliated Hospital of Zhengzhou University. A precise excision of giant lymphatic vascular malformation with intracapsular hemorrhage was performed to achieve clinical cure. The patient was followed up for 3 months with no recurrence, functional and aesthetic result.

Objective:To investigate the expression of syndecan-1 (SDC1) in human venous malformations and the effect of syndecan-1 (SDC1) silences on migration, invasion and angiogenesis of human umbilical vein endothelial cells (HUVECs).Methods:Pathological samples of venous malformation were selected from 20 patients with hemangioma surgically resected in the Third Affiliated Hospital of Zhengzhou University from December 2020 to June 2021 (10 males and 10 females, aged 1-57 years, median age 7 years ). HUVECs was purchased from American Type Culture Collection (ATCC ). Immunohistochemistry was used to detect the expression of SDC1 in venous malformations. The cytological experiments of HUVECs cultured in vitro were divided into two groups, transfected SDC1 small interfering RNA (siRNA) (si-SDC1 group) and control siRNA (control group), respectively. The siRNA with the best silencing effect was selected by real-time quantitative PCR and Western Blot method for follow-up experiments. Then the ability of HUVECs migration, invasion and angiogenesis was detected by scratch test, Transwell migration and invasion test and angiogenesis test, respectively.Results:SDC1 was positive in 13 of the 20 venous malformations and was mainly expressed in the cytoplasm of venous endothelial cells. Compared with HUVECs cells in NC group, the expression of SDC1 mRNA and protein in HUVECs cells in si-SDC1 group decreased, indicated that the synthesized siRNA targeting SDC1 could silence the expression of SDC1 , and the ability of HUVECs migration, invasion and angiogenesis were enhanced in si-SDC1 group.Conclusions:SDC1 was positively expressed in venous malformations. After silencing SDC1, the migration, invasion and tube formation ability of HUVECs were enhanced.

Objective:To investigate the expression of syndecan-1 (SDC1) in human venous malformations and the effect of SDC1 silencing on the migration, invasion and angiogenesis abilities of human umbilical vein endothelial cells (HUVECs).Methods:Twenty surgically resected samples of venous malformation were collected from 20 patients with hemangioma at the Third Affiliated Hospital of Zhengzhou University from December 2020 to June 2021 (10 males and 10 females, aged 1-57 years, median age 7 years). HUVECs were purchased from American Type Culture Collection (ATCC). Immunohistochemistry staining was used to detect the expression of SDC1 in venous malformations. HUVECs cultured in vitro were divided into two groups, and were transfected with SDC1 small interfering RNA (siRNA) (si-SDC1 group) or control siRNA (control group), respectively. The siRNA with the best silencing effect was screened and tested by real-time quantitative PCR and Western blotting for follow-up experiments. The migration, invasion and angiogenesis abilities of HUVECs were measured by scratch test, Transwell migration and invasion test, and angiogenesis test, respectively. Results:(1) SDC1 was positive in 13(65.0%) of the 20 venous malformations and was mainly expressed in the cytoplasm of venous endothelial cells. (2) Compared with HUVECs in the control group, the expression of SDC1 mRNA and protein in HUVECs cells in si-SDC1 group both decreased ( P<0.05), indicating the synthesized siRNA targeting SDC1 could silence the expression of SDC1. (3) The migration, invasion and angiogenesis abilities of HUVECs were enhanced in si-SDC1 group( P<0.05). Conclusions:SDC1 was expressed in most venous malformations. After silencing SDC1, the migration, invasion and tube formation abilities of HUVECs were enhanced.

Giant lymphatic vascular malformation with intracapsular hemorrhage is rare in neonates, and its incidence gradually increased in recent years. In consideration of physiological characteristics of neonates, the treatment is of great value. In January 2021, a 1-hour-old boy with facial and cervical giant lymphatic malformation and intracapsular hemorrhage was admitted to the Department of Hemangioma Surgery, the Third Affiliated Hospital of Zhengzhou University. A precise excision of giant lymphatic vascular malformation with intracapsular hemorrhage was performed to achieve clinical cure. The patient was followed up for 3 months with no recurrence, functional and aesthetic result.

Objective:To investigate the expression of syndecan-1 (SDC1) in human venous malformations and the effect of syndecan-1 (SDC1) silences on migration, invasion and angiogenesis of human umbilical vein endothelial cells (HUVECs).Methods:Pathological samples of venous malformation were selected from 20 patients with hemangioma surgically resected in the Third Affiliated Hospital of Zhengzhou University from December 2020 to June 2021 (10 males and 10 females, aged 1-57 years, median age 7 years ). HUVECs was purchased from American Type Culture Collection (ATCC ). Immunohistochemistry was used to detect the expression of SDC1 in venous malformations. The cytological experiments of HUVECs cultured in vitro were divided into two groups, transfected SDC1 small interfering RNA (siRNA) (si-SDC1 group) and control siRNA (control group), respectively. The siRNA with the best silencing effect was selected by real-time quantitative PCR and Western Blot method for follow-up experiments. Then the ability of HUVECs migration, invasion and angiogenesis was detected by scratch test, Transwell migration and invasion test and angiogenesis test, respectively.Results:SDC1 was positive in 13 of the 20 venous malformations and was mainly expressed in the cytoplasm of venous endothelial cells. Compared with HUVECs cells in NC group, the expression of SDC1 mRNA and protein in HUVECs cells in si-SDC1 group decreased, indicated that the synthesized siRNA targeting SDC1 could silence the expression of SDC1 , and the ability of HUVECs migration, invasion and angiogenesis were enhanced in si-SDC1 group.Conclusions:SDC1 was positively expressed in venous malformations. After silencing SDC1, the migration, invasion and tube formation ability of HUVECs were enhanced.

Objective:To investigate the expression of syndecan-1 (SDC1) in human venous malformations and the effect of SDC1 silencing on the migration, invasion and angiogenesis abilities of human umbilical vein endothelial cells (HUVECs).Methods:Twenty surgically resected samples of venous malformation were collected from 20 patients with hemangioma at the Third Affiliated Hospital of Zhengzhou University from December 2020 to June 2021 (10 males and 10 females, aged 1-57 years, median age 7 years). HUVECs were purchased from American Type Culture Collection (ATCC). Immunohistochemistry staining was used to detect the expression of SDC1 in venous malformations. HUVECs cultured in vitro were divided into two groups, and were transfected with SDC1 small interfering RNA (siRNA) (si-SDC1 group) or control siRNA (control group), respectively. The siRNA with the best silencing effect was screened and tested by real-time quantitative PCR and Western blotting for follow-up experiments. The migration, invasion and angiogenesis abilities of HUVECs were measured by scratch test, Transwell migration and invasion test, and angiogenesis test, respectively. Results:(1) SDC1 was positive in 13(65.0%) of the 20 venous malformations and was mainly expressed in the cytoplasm of venous endothelial cells. (2) Compared with HUVECs in the control group, the expression of SDC1 mRNA and protein in HUVECs cells in si-SDC1 group both decreased ( P<0.05), indicating the synthesized siRNA targeting SDC1 could silence the expression of SDC1. (3) The migration, invasion and angiogenesis abilities of HUVECs were enhanced in si-SDC1 group( P<0.05). Conclusions:SDC1 was expressed in most venous malformations. After silencing SDC1, the migration, invasion and tube formation abilities of HUVECs were enhanced.